Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.

Trial Profile

A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Exenatide (Primary) ; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DURATION-2
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2018 Results assessing the efficacy and safety of exenatide once weekly across 10 comparator-controlled studies from the DURATION clinical programme (n=2251) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 31 Aug 2018 Biomarkers information updated
    • 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top